Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

NCT01368276 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

NCT00769704 ·Status: COMPLETED ·Phase: PHASE3

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

NCT04068181 ·Status: COMPLETED ·Phase: PHASE2

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

NCT02110355 ·Status: COMPLETED ·Phase: PHASE1

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

NCT00289016 ·Status: COMPLETED ·Phase: PHASE2

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

NCT02965716 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

NCT02574260 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085 ·Status: COMPLETED ·Phase: PHASE2

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872 ·Status: COMPLETED ·Phase: PHASE2

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

NCT04544202 ·Status: NO_LONGER_AVAILABLE

Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma

NCT00747825 ·Status: TERMINATED ·Phase: PHASE1

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NCT02819843 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

NCT01437605 ·Status: TERMINATED ·Phase: PHASE2

Expanded Access Program With Nivolumab to Treat Melanoma

NCT02142218 ·Status: NO_LONGER_AVAILABLE

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

NCT03064763 ·Status: COMPLETED ·Phase: PHASE1

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

NCT05561491 ·Status: WITHDRAWN ·Phase: PHASE2

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

NCT00735332 ·Status: TERMINATED ·Phase: PHASE2

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

NCT00003789 ·Status: COMPLETED ·Phase: PHASE3

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

NCT02535078 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Taxoprexin® Treatment for Advanced Eye Melanoma

NCT00244816 ·Status: COMPLETED ·Phase: PHASE2

CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma

NCT03727789 ·Status: TERMINATED ·Phase: PHASE1

Treatment Use Study for Advanced Melanoma.

NCT00584493 ·Status: NO_LONGER_AVAILABLE

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

NCT05655312 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

NCT00457418 ·Status: COMPLETED ·Phase: PHASE1

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

NCT03178851 ·Status: COMPLETED ·Phase: PHASE1